IP Library › Patent Application 13210178
Patent Application
App. No. 13/210,178

MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/210,178
Abstract

The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin α v β 3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin α v β 3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

Claims (11)

1 . The method of modulators of cytokine mediated signalling pathways in combination with integrin α v β 3 receptor antagonists for the manufacture of medicaments for the treatment or prevention of diseases.

2 . The method of claim 1 for the treatment or prevention of inflammatory or autoimmune disorders.

3 . The method of claim 2 for the treatment or prevention of rheumatoid arthritis.

4 . The method of claim 1 wherein the modulator of cytokine mediated signalling pathways is a TNFα inhibitor.

5 . A pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin α v β 3 receptor antagonist.

6 . The composition of claim 5 for use as a medicament.

7 . The composition of claim 6 for curing inflammatory or autoimmune disorders.

8 . The method of claim 4 for the manufacture of a medicament for the treatment or prevention of diseases.

9 . The method of claim 8 for the treatment or prevention of inflammatory or autoimmune disorders.

10 . The method of claim 9 for the treatment or prevention of rheumatoid arthritis.

11 . A kit comprising as pharmaceutical agent a modulator of cytokine mediated signalling pathways or/and an integrin α v β 3 receptor antagonist together with an instruction for use 40 of this pharmaceutical agents in combination for simultaneous, separate, or temporal graduated application for the treatment or prevention of diseases.